Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21296491
Cho JH, et al. (2011) The TSP motif in AP180 inhibits phospholipase D1 activity resulting in increased efficacy of anticancer drug via its direct binding to carboxyl terminal of phospholipase D1. Cancer Lett 302, 144-54 21296491
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.

S313-p - SNAP-91 (human)
Modsite: SPATTVTsPNSTPAK SwissProt Entrez-Gene
Orthologous residues
SNAP‑91 (human): S313‑p, SNAP‑91 (mouse): S313‑p, SNAP‑91 (rat): S313‑p, SNAP‑91 iso2 (rat): S313‑p
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site
Disease tissue studied:  cervical cancer, cervical squamous cell carcinoma, gastric cancer, gastric carcinoma
Relevant cell lines - cell types - tissues:  KATO III (gastric), SiHa (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PLD1 (human) Induces enzymatic activity, inhibited co-immunoprecipitation